<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="32c90e66-1641-7c04-e063-6394a90ac247"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use MEMANTINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for MEMANTINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULES.</content>
      <br/>
      <br/>
      <content styleCode="bold">MEMANTINE HYDROCHLORIDE extended-release capsules, for oral use</content>
      <br/>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 2003</content>
   </title>
   <effectiveTime value="20250414"/>
   <setId root="a74050c4-5a37-4fa1-85d9-85831525cfeb"/>
   <versionNumber value="14"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="039452765"/>
            <name>Slate Run Pharmaceuticals, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <id root="1.3.6.1.4.1.519.1" extension="527225336"/>
                  <name>Yichang Humanwell Pharmaceutical Co., Ltd.</name>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="421371958"/>
                        <name>Yichang Humanwell Oral Solid Dosage Plant</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70436-054" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70436-055" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70436-056" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="70436-057" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="32c91768-5dc0-9945-e063-6294a90a79a2"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250414"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70436-054" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Memantine Hydrochloride</name>
                        <formCode code="C42916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>memantine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7Z8S9VYZ4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T4V6TWG28D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYETHYL CELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C9H2L21V7U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEDIUM-CHAIN TRIGLYCERIDES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2UMI9U37CP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OLEIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZH3C48M4T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="7"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JY0WD0UA60" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEMANTINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="W8O17SJF3T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MEMANTINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70436-054-04" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20211115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA211100" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20211115"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText>buff (opaque)</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">YH;123</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="14" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70436-055" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Memantine Hydrochloride</name>
                        <formCode code="C42916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>memantine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7Z8S9VYZ4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T4V6TWG28D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYETHYL CELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C9H2L21V7U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEDIUM-CHAIN TRIGLYCERIDES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2UMI9U37CP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OLEIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZH3C48M4T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="14"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JY0WD0UA60" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEMANTINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="W8O17SJF3T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MEMANTINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70436-055-04" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20211115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70436-055-06" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20211115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA211100" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20211115"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="yellow" xsi:type="CE">
                              <originalText>buff (opaque)</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="green" xsi:type="CE">
                              <originalText>dark green (opaque)</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">YH;124</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="14" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70436-056" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Memantine Hydrochloride</name>
                        <formCode code="C42916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>memantine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7Z8S9VYZ4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T4V6TWG28D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYETHYL CELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C9H2L21V7U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEDIUM-CHAIN TRIGLYCERIDES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2UMI9U37CP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OLEIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="WZH3C48M4T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POTASSIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="21"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JY0WD0UA60" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEMANTINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="W8O17SJF3T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MEMANTINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70436-056-04" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20211115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA211100" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20211115"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>white (opaque)</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="green" xsi:type="CE">
                              <originalText>dark green (opaque)</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">YH;125</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="14" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="70436-057" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Memantine Hydrochloride</name>
                        <formCode code="C42916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE, EXTENDED RELEASE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>memantine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7Z8S9VYZ4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="T4V6TWG28D" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYETHYL CELLULOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C9H2L21V7U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEDIUM-CHAIN TRIGLYCERIDES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2UMI9U37CP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OLEIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="28"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="JY0WD0UA60" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MEMANTINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="W8O17SJF3T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MEMANTINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70436-057-04" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20211115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="90" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="70436-057-06" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20211115"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA211100" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20211115"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="green" xsi:type="CE">
                              <originalText>dark green (opaque)</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">YH;126</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="_1_INDICATIONS_AND">
               <id root="32c90e66-1642-7c04-e063-6394a90ac247"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1 </content>
                  <content styleCode="bold">INDICATIONS AND USAGE</content>
               </title>
               <text>
                  <paragraph>Memantine Hydrochloride Extended-Release Capsules are indicated for the treatment of moderate to severe dementia of the Alzheimers type.</paragraph>
               </text>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Memantine Hydrochloride Extended-Release Capsules areaN-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimers type. (
 
    <linkHtml href="#_1_INDICATIONS_AND">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="32c90e66-1643-7c04-e063-6394a90ac247"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2 </content>
                  <content styleCode="bold">DOSAGE AND ADMINISTRATION</content>
               </title>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended starting dose ofmemantine hydrochloride extended-release capsules is 7 mg once daily; the dose should be increased in 7 mg increments to the recommended maintenance dose of 28 mg once daily; the minimum recommended interval between dose increases is one week.(
  
     <linkHtml href="#_2_1_Recommended_Dosing">2.1</linkHtml>)
 
    </item>
                           <item>Patients with severe renal impairment: the recommended maintenance dose ofmemantine hydrochloride extended-release capsules is 14mg once daily. (
  
     <linkHtml href="#_2_3_Dosing_in">2.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_2_1_Recommended_Dosing">
                     <id root="32c90e66-1644-7c04-e063-6394a90ac247"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1 </content>
                        <content styleCode="bold">Recommended Dosing</content>
                     </title>
                     <text>
                        <paragraph>The dosage ofmemantine hydrochloride extended-release capsules shown to be effective in a controlled clinical trial is 28mg once daily.</paragraph>
                        <paragraph>The recommended starting dose ofmemantine hydrochloride extended-release capsules is 7mg once daily. The dose should be increased in 7mg increments to the recommended maintenance dose of 28mg once daily. The minimum recommended interval between dose increases is one week. The dose should only be increased if the previous dose has been well tolerated. The maximum recommended dose is 28mg once daily.</paragraph>
                        <paragraph>Memantine hydrochloride extended-release capsulescan be taken with or without food.Memantine hydrochloride extended-release capsules can be taken intact or may be opened, sprinkled on applesauce, and thereby swallowed. The entire contents of eachmemantine hydrochloride extended-release capsuleshould be consumed; the dose should not be divided.</paragraph>
                        <paragraph>Except when opened and sprinkled on applesauce, as described above,memantine hydrochloride extended-release capsules should be swallowed whole.Memantine hydrochloride extended-release capsules should not be divided, chewed, or crushed.</paragraph>
                        <paragraph>If a patient misses a single dose of memantine hydrochloride extended-release capsules, that patient should not double up on the next dose. The next dose should be taken as scheduled. If a patient fails to takememantine hydrochloride extended-release capsules for several days, dosing may need to be resumed at lower doses and retitrated as described above.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32c90e66-1645-7c04-e063-6394a90ac247"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2 </content>
                        <content styleCode="bold">Switching fromMemantine Hydrochloride Tablets to Memantine Hydrochloride Extended-Release Capsules</content>
                     </title>
                     <text>
                        <paragraph>Patients treated withmemantine hydrochloride tablets may be switched tomemantine hydrochloride extended-release capsules as follows:</paragraph>
                        <paragraph>It is recommended that a patient who is on a regimen of 10mgtwice daily ofmemantine hydrochloride tablets be switched tomemantine hydrochloride extended-release capsules 28mgonce daily capsules the day following the last dose of10mg memantine hydrochloride tablets. There is no study addressing the comparativeefficacy of these 2 regimens.</paragraph>
                        <paragraph>In a patient with severe renal impairment, it is recommended that a patient who is on a regimen of 5mgtwice daily ofmemantine hydrochloride tablets be switched tomemantine hydrochloride extended-release capsules 14mgonce daily capsules the day following the last dose of 5mg memantine hydrochloride tablets.</paragraph>
                     </text>
                     <effectiveTime value="20210106"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_3_Dosing_in">
                     <id root="32c90e66-1646-7c04-e063-6394a90ac247"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.3 </content>
                        <content styleCode="bold">Dosing in</content>
                        <content styleCode="bold">Patients with Renal Impairment</content>
                     </title>
                     <text>
                        <paragraph>In patients with severe renal impairment (creatinine clearance of 5 to 29 mL/min, based on the Cockcroft-Gault equation), the recommended maintenance dose (and maximum recommended dose)is 14mg/day
 
  <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3_DOSAGE_FORMS">
               <id root="32c90e66-1647-7c04-e063-6394a90ac247"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3 </content>
                  <content styleCode="bold">DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>Each capsule contains7mg, 14mg, 21mg,or 28mg of memantine hydrochloride, USP.</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>The 7mg capsules arean opaque buff capsule, with YH black imprint on the cap and 123 black imprint on the body.</item>
                     <item>The 14mg capsules arean opaque buff cap and opaque dark green body capsule, with YH black imprint on the cap and 124 black imprint on the body.</item>
                     <item>The 21mg capsules arean opaque white cap and opaque dark green body capsule, with YH black imprint on the cap and 125 black imprint on the body.</item>
                     <item>The 28mg capsules area dark green opaque capsule, with YH white imprint on the cap and 126 white imprint on the body.</item>
                  </list>
               </text>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Memantine hydrochloride extended-release capsules areavailable as an extended-release capsule in the following strengths: 7 mg, 14 mg, 21 mg, 28 mg. (
  
     <linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_4_CONTRAINDICATIONS">
               <id root="32c90e66-1648-7c04-e063-6394a90ac247"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4 </content>
                  <content styleCode="bold">CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>Memantine Hydrochloride Extended-Release Capsules arecontraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation
 
  <content styleCode="italics">.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Memantine Hydrochloride Extended-Release Capsules arecontraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. (
  
     <linkHtml href="#_4_CONTRAINDICATIONS">4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="32c90e66-1649-7c04-e063-6394a90ac247"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5 </content>
                  <content styleCode="bold">WARNINGS AND PRECAUTIONS</content>
               </title>
               <effectiveTime value="20250410"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Conditions that raise urine pH may decrease the urinary elimination of memantine resulting in increased plasma levels of memantine. (
  
     <linkHtml href="#_5_1_Genitourinary_Conditions">5.1</linkHtml>,
  
     <linkHtml href="#_7_1_Drugs_That">7.1</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1_Genitourinary_Conditions">
                     <id root="32c90e66-164a-7c04-e063-6394a90ac247"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1 </content>
                        <content styleCode="bold">Genitourinary Conditions</content>
                     </title>
                     <text>
                        <paragraph>Conditions that raise urine pH may decrease the urinary elimination of memantine resulting in increased plasma levels of memantine
 
  <content styleCode="italics">[see Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_7_1_Drugs_That">7.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20200407"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="32c90e66-164b-7c04-e063-6394a90ac247"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6 </content>
                  <content styleCode="bold">ADVERSE REACTIONS</content>
               </title>
               <effectiveTime value="20250415"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most commonly observed adverse reactions occurring at a frequency of at least 5% and greater than placebo with administration ofmemantine hydrochloride extended-release capsules 28mg/day were headache, diarrhea and dizziness. (
 
    <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>  To report SUSPECTED ADVERSE REACTIONS, contactSlate Run Pharmaceuticals, LLC at1-888-341-9214 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
    </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_6_1_Clinical_Trials">
                     <id root="32c90e66-164c-7c04-e063-6394a90ac247"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.1 </content>
                        <content styleCode="bold">Clinical Trial</content>
                        <content styleCode="bold">s</content>
                        <content styleCode="bold">Experience</content>
                     </title>
                     <text>
                        <paragraph>Memantine hydrochloride extended-release capsules were evaluated in a double-blind placebo-controlled trial in which a total of 676patients with moderate to severe dementia of the Alzheimers type (341 patients on memantine hydrochloride extended-release capsules 28mg/day and 335 patients on placebo) were treated for up to 24 weeks.</paragraph>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adverse Reactions Leading to Discontinuation</content>
                        </paragraph>
                        <paragraph>In the placebo-controlled clinical trial of memantine hydrochloride extended-release capsules, the proportion of patients in thememantine hydrochloride extended-release capsules group and the placebo group who discontinued treatment due to adverse reactions was 10% and 6%, respectively. The most common adverse reaction that led to treatment discontinuation in thememantine hydrochloride extended-release capsules group was dizziness, at a rate of 1.5%.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Most Common Adverse Reactions</content>
                        </paragraph>
                        <paragraph>The most commonly observed adverse reactions seen in patients administeredmemantine hydrochloride extended-release capsules in the controlled clinical trial, defined as those occurring at a frequency of at least 5% in thememantine hydrochloride extended-release capsules group and at a frequency higher than placebo,were headache, diarrhea and dizziness.</paragraph>
                        <paragraph>Table 1 lists adverse reactions that were observed at an incidence of 2% in thememantine hydrochloride extended-release capsules group and occurred at a rate greater than placebo.</paragraph>
                        <table>
                           <caption>Table 1: Adverse Reactions Observed with a Frequency of 2% in theMemantine Hydrochloride Extended-Release Capsules Group and at a Rate Greater than Placebo</caption>
                           <col width="249"/>
                           <col width="167"/>
                           <col width="174"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Adverse</content>
                                    <content styleCode="bold">R</content>
                                    <content styleCode="bold">eaction</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">(n=335)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Memantine Hydrochloride Extended-Release Capsules28</content>
                                    <content styleCode="bold">mg</content>
                                    <br/>
                                    <content styleCode="bold">(n=341)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold"> Gastrointestinal Disorders</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Diarrhea</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">4</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Constipation</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Abdominal pain</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Vomiting</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold"> Infections and</content>
                                    <content styleCode="bold">I</content>
                                    <content styleCode="bold">nfestations</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Influenza</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">3</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold"> Investigations</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Weight, increased</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold"> Musculoskeletal and</content>
                                    <content styleCode="bold">C</content>
                                    <content styleCode="bold">onnective</content>
                                    <content styleCode="bold">T</content>
                                    <content styleCode="bold">issue</content>
                                    <content styleCode="bold">D</content>
                                    <content styleCode="bold">isorders</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Back pain</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold"> Nervous</content>
                                    <content styleCode="bold">S</content>
                                    <content styleCode="bold">ystem</content>
                                    <content styleCode="bold">D</content>
                                    <content styleCode="bold">isorders</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Headache</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">5</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Dizziness</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Somnolence</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold"> Psychiatric</content>
                                    <content styleCode="bold">D</content>
                                    <content styleCode="bold">isorders</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Anxiety</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">3</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Depression</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Aggression</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold"> Renal and</content>
                                    <content styleCode="bold">U</content>
                                    <content styleCode="bold">rinary</content>
                                    <content styleCode="bold">D</content>
                                    <content styleCode="bold">isorders</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Urinary incontinence</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold"> Vascular</content>
                                    <content styleCode="bold">D</content>
                                    <content styleCode="bold">isorders</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                                 <td align="center" styleCode="Lrule Rrule Toprule"/>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Hypertension</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">2</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule">  Hypotension</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">2</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Seizure</content>
                        </paragraph>
                        <paragraph>Memantine has not been systematically evaluated in patients with a seizure disorder. In clinical trials of memantine, seizures occurred in 0.3% of patients treated with memantine and 0.6% of patients treated with placebo.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32c90e66-164d-7c04-e063-6394a90ac247"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.</content>
                        <content styleCode="bold">2 </content>
                        <content styleCode="bold">Post</content>
                        <content styleCode="bold">m</content>
                        <content styleCode="bold">arketing</content>
                        <content styleCode="bold">Experience</content>
                     </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of memantine. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions include:</paragraph>
                        <paragraph>Blood and Lymphatic System Disorders:agranulocytosis, leukopenia (including neutropenia), pancytopenia, thrombocytopenia,thrombotic thrombocytopenic purpura.</paragraph>
                        <paragraph>Cardiac Disorders: cardiac failure congestive.</paragraph>
                        <paragraph>Gastrointestinal Disorders:pancreatitis.</paragraph>
                        <paragraph>Hepatobiliary Disorders: hepatitis.</paragraph>
                        <paragraph>Psychiatric Disorders:suicidal ideation.</paragraph>
                        <paragraph>Renal and Urinary Disorders: acute renal failure (including increased creatinine and renal insufficiency).</paragraph>
                        <paragraph>Skin Disorders: Stevens Johnson syndrome.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="32c90e66-164e-7c04-e063-6394a90ac247"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7 </content>
                  <content styleCode="bold">DRUG INTERACTIONS</content>
               </title>
               <effectiveTime value="20250415"/>
               <component>
                  <section ID="_7_1_Drugs_That">
                     <id root="32c90e66-164f-7c04-e063-6394a90ac247"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1 </content>
                        <content styleCode="bold">Drugs That Make Urine Alkaline</content>
                     </title>
                     <text>
                        <paragraph>The clearance of memantine was reduced by about 80% under alkaline urine conditions at pH 8. Therefore, alterations of urine pH towards the alkaline condition may lead to an accumulation of the drug with a possible increase in adverse effects. Urine pH is altered by diet, drugs (e.g., carbonic anhydrase inhibitors, sodium bicarbonate) and clinical state of the patient (e.g., renal tubular acidosis or severe infections of the urinary tract). Hence, memantine should be used with caution under these conditions.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32c90e66-1650-7c04-e063-6394a90ac247"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.</content>
                        <content styleCode="bold">2 </content>
                        <content styleCode="bold">Use with</content>
                        <content styleCode="bold">O</content>
                        <content styleCode="bold">th</content>
                        <content styleCode="bold">er N-methyl-D-aspartate (NMDA) A</content>
                        <content styleCode="bold">ntagonists</content>
                     </title>
                     <text>
                        <paragraph>The combined use ofmemantine hydrochloride extended-release capsules with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="32c90e66-1651-7c04-e063-6394a90ac247"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8 </content>
                  <content styleCode="bold">USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20250415"/>
               <component>
                  <section>
                     <id root="32c90e66-1652-7c04-e063-6394a90ac247"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1 </content>
                        <content styleCode="bold">Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no adequate data on the development risk associated with the use of memantine hydrochloride extended-release capsules in pregnant women.</paragraph>
                        <paragraph>Adverse developmental effects (decreased body weight and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. These doses are higher than those used in humans at the maximum recommended daily dose of memantine hydrochloride extended-release capsules
 
  <content styleCode="italics">[see Data]</content>.

 </paragraph>
                        <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Oral administration of memantine (0, 2, 6, or 18 mg/kg/day) to rats during the period of organogenesis resulted in decreased skeletal ossification in fetuses at the highest dose tested. The higher no-effect dose for adverse developmental effects (6 mg/kg) is 2 times the maximum recommended human daily dose (MRHD) of memantine hydrochloride extended-release capsules (28 mg) on a body surface area (mg/m
 
  <sup>2</sup>) basis.

 </paragraph>
                        <paragraph>Oral administration of memantine to rabbits (0, 3, 10, or 30 mg/kg/day) during the period of organogenesis resulted in no adverse developmental effects. The highest dose tested is approximately 20 times the MRHD of memantine hydrochloride extended-release capsules on a mg/m
 
  <sup>2</sup>basis.

 </paragraph>
                        <paragraph>In rats, memantine (0, 2, 6, or 18 mg/kg/day) was administered orally prior to and throughout mating and, in females, through the period of organogenesis or continuing throughout lactation to weaning. Decreased skeletal ossification in fetuses and decreased body weight in pups were observed at the highest dose tested. The higher no-effect dose for adverse developmental effects (6 mg/kg/day) is 2 times the MRHD of memantine hydrochloride extended-release capsules on a mg/m
 
  <sup>2</sup>basis.

 </paragraph>
                        <paragraph>Oral administration of memantine (0, 2, 6, or 18 mg/kg/day) to rats from late gestation throughout lactation to weaning, resulted in decreased pup weights at the highest dose tested. The higher no-effect dose (6 mg/kg/day) is approximately 2 times the MRHD of memantine hydrochloride extended-release capsules on a mg/m
 
  <sup>2</sup>basis.

 </paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32c90e66-1653-7c04-e063-6394a90ac247"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8.2 </content>
                        <content styleCode="bold">Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk</content>
                           <content styleCode="underline">Summary</content>
                        </paragraph>
                        <paragraph>Therearenodataonthepresenceofmemantineinhumanmilk,theeffectsonthebreastfedinfant,ortheeffectsofmemantine hydrochloride extended-release capsules onmilkproduction.</paragraph>
                        <paragraph>Thedevelopmentalandhealthbenefitsofbreastfeedingshouldbeconsideredalongwiththemothersclinicalneedformemantine hydrochloride extended-release capsules andanypotentialadverseeffectsonthebreastfedinfantfrommemantine hydrochloride extended-release capsules orfromtheunderlyingmaternalcondition.</paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32c90e66-1654-7c04-e063-6394a90ac247"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.</content>
                        <content styleCode="bold">4 </content>
                        <content styleCode="bold">Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>Safety and effectivenessin pediatric patients have not been established.</paragraph>
                        <paragraph>Memantine failed to demonstrate efficacy in two 12-week controlled clinical studies of 578 pediatric patients aged 6 to 12 years with autism spectrum disorders (ASD), including autism, Aspergers disorder and Pervasive Development Disorder-Not Otherwise Specified (PDD-NOS). Memantine has not been studied in pediatric patients under 6 years of age or over 12 years of age. Memantine treatment was initiated at 3 mg/day and the dose was escalated to the target dose (weight-based) by week 6. Oral doses of memantine 3, 6, 9, or 15 mg extended-release capsules were administered once daily to patients with weights &lt;20 kg, 20 to 39 kg, 40 to 59 kg and 60 kg, respectively.</paragraph>
                        <paragraph>In a randomized, 12-week double-blind, placebo-controlled parallel study (Study A) in patients with autism, there was no statistically significant difference in the Social Responsiveness Scale (SRS) total raw score between patients randomized to memantine (n=54) and those randomized to placebo (n=53). In a 12-week responder-enriched randomized withdrawal study (Study B) in 471 patients with ASD, there was no statistically significant difference in the loss of therapeutic response rates between patients randomized to remain on full-dose memantine (n=153) and those randomized to switch to placebo (n=158).</paragraph>
                        <paragraph>The overall safety profile of memantine in pediatric patients was generally consistent with the known safety profile in adults
 
  <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                        <paragraph>In Study A, the adverse reactions in the memantine group (n=56) that were reported in at least 5% of patients and twice that in the placebo group (N=58) are listed in Table 2:</paragraph>
                        <table>
                           <caption>Table 2: Study A Commonly Reported Adverse Reactionswith a Frequency 5% and Twice That of Placebo</caption>
                           <col width="198"/>
                           <col width="109"/>
                           <col width="108"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Adverse</content>
                                    <content styleCode="bold">Reaction</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Memantine</content>
                                    <br/>
                                    <content styleCode="bold">N=56</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Placebo</content>
                                    <br/>
                                    <content styleCode="bold">N=58</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"> Cough</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">8.9%</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">3.4%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"> Influenza</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">7.1%</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">3.4%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"> Rhinorrhea</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">5.4%</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">0%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"> Agitation</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">5.4%</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1.7%</td>
                              </tr>
                              <tr>
                                 <td colspan="3" align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Discontinuations due to</content>
                                    <content styleCode="bold">A</content>
                                    <content styleCode="bold">dverse</content>
                                    <content styleCode="bold">R</content>
                                    <content styleCode="bold">eaction</content>
                                    <content styleCode="bold">s</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"> Aggression</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">3.6%</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1.7%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"> Irritability</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1.8%</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">3.4%</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule Toprule">
                                    <sup> a</sup>Reported adverse reactions leading to discontinuation in more than one patient in either treatment group.
   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The adverse reactions that were reported in at least 5% of patients in the 12 to 48 week open-label study to identify responders to enroll in Study B are listed in Table 3.</paragraph>
                        <table>
                           <caption>Table 3:12 to 48 Week Open Label Lead-In study to Study BCommonly Reported Adverse Reactions with a Frequency 5%</caption>
                           <col width="213"/>
                           <col width="213"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Adverse</content>
                                    <content styleCode="bold">Reaction</content>
                                 </td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Memantine</content>
                                    <br/>
                                    <content styleCode="bold">N=903</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"> Headache</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">8.0%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"> Nasopharyngitis</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">6.3%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"> Pyrexia</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">5.8%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"> Irritability</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">5.4%</td>
                              </tr>
                              <tr>
                                 <td colspan="2" align="center" styleCode="Lrule Rrule Toprule">
                                    <content styleCode="bold">Discontinuations due to</content>
                                    <content styleCode="bold">A</content>
                                    <content styleCode="bold">dverse</content>
                                    <content styleCode="bold">R</content>
                                    <content styleCode="bold">eaction</content>
                                    <content styleCode="bold">s</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"> Irritability</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1.2%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule Toprule"> Aggression</td>
                                 <td align="center" styleCode="Lrule Rrule Toprule">1.0%</td>
                              </tr>
                              <tr>
                                 <td colspan="2" styleCode="Lrule Rrule Toprule">
                                    <sup> a</sup>At least 1% incidence of adverse reactions leading to premature discontinuation.
   
    </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>In the randomized withdrawal study (Study B), the adverse reaction in patients randomized to placebo (n=160) and reported in at least 5% of patients and twice that of the full-dose memantine treatment group (n=157) was irritability (5.0% vs 2.5%).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Juvenile Animal Study</content>
                        </paragraph>
                        <paragraph>In a juvenile animal study, male and female juvenile rats were administered memantine (15, 30, and 45 mg/kg/day) starting on postnatal day (PND) 14 through PND 70. Body weights were reduced at 45 mg/kg/day. Delays in sexual maturation were noted in male and female rats at doses 30 mg/kg/day. Memantine induced neuronal lesions in several areas of the brain on PND 15 and 17 at doses 30 mg/kg/day. Behavioral toxicity (decrease percent of auditory startle habituation) was noted for animals in the 45 mg/kg/day dose group. The 15 mg/kg/day dose was considered the No-Observed Adverse-Effect-Level (NOAEL) for this study.</paragraph>
                        <paragraph>In a second juvenile rat toxicity study, male and female juvenile rats were administered memantine (1, 3, 8, 15, 30, and 45 mg/kg/day) starting on postnatal day (PND) 7 through PND 70. Due to early memantine-related mortality, the 30 and 45 mg/kg/day dose groups were terminated without further evaluation. Memantine induced apoptosis or neuronal degeneration in several areas of the brain on PND 8, 10, and 17 at a dose of 15 mg/kg/day. The NOAEL for apoptosis and neuronal degeneration was 8 mg/kg/day. Behavioral toxicity (effects on motor activity, auditory startle habituation, and learning and memory) was noted at doses 3 mg/kg/day during treatment, but was not seen after drug discontinuation. Therefore, the 1 mg/kg/day dose was considered the NOAEL for the neurobehavioral effect in this study.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32c90e66-1655-7c04-e063-6394a90ac247"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5 </content>
                        <content styleCode="bold">Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>The majority of people with Alzheimers disease are 65 years of age and older. In the clinical study of memantine hydrochloride extended-release, the mean age of patients was approximately 77 years; over 91% of patients were 65 years and older, 67% were 75 years and older, and 14% were at or above 85 years of age. The efficacy and safety data presented in the clinical trials section were obtained from these patients. There were no clinically meaningful differences in most adverse reactions reported by patient groups 65 years old and &lt;65 years old.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32c90e66-1656-7c04-e063-6394a90ac247"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.6 </content>
                        <content styleCode="bold">Renal Impairment</content>
                     </title>
                     <text>
                        <paragraph>No dosage adjustment is needed in patients with mild or moderate renal impairment. A dosage reduction is recommended in patients with severe renal impairment
 
  <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_3_Dosing_in">2.3</linkHtml>
                           </content>
                           <content styleCode="italics">) and Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32c90e66-1657-7c04-e063-6394a90ac247"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.7 </content>
                        <content styleCode="bold">Hepatic Impairment</content>
                     </title>
                     <text>
                        <paragraph>No dosage adjustment is needed in patients with mild or moderate hepatic impairment.Memantine hydrochloride extended-release capsules were not studied in patients with severe hepatic impairment
 
  <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="32c90e66-1658-7c04-e063-6394a90ac247"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10 </content>
                  <content styleCode="bold">OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>Signs and symptoms most often accompanying overdosage with other formulations of memantine in clinical trials and from worldwide marketing experience, alone or in combination with other drugs and/or alcohol, include agitation, asthenia, bradycardia, confusion, coma, dizziness, ECG changes, increased blood pressure, lethargy, loss of consciousness, psychosis, restlessness, slowed movement, somnolence, stupor, unsteady gait, visual hallucinations, vertigo, vomiting, and weakness. The largest known ingestion of memantine worldwide was 2 grams in a patient who took memantine in conjunction with unspecified antidiabetic medications. This person experienced coma, diplopia, and agitation, but subsequently recovered.</paragraph>
                  <paragraph>One patient participating in a memantine hydrochloride extended-release capsules clinical trial unintentionally took 112 mg of memantine hydrochloride extended-release capsules daily for 31 days and experienced an elevated serum uric acid, elevated serum alkaline phosphatase, and low platelet count.</paragraph>
                  <paragraph>Fatal outcome has been very rarely been reported with memantine, and the relationship to memantine was unclear.</paragraph>
                  <paragraph>Because strategies for the management of overdose are continually evolving, it is advisable to contact a poison control center to determine the latest recommendations for the management of an overdose of any drug. As in any cases of overdose, general supportive measures should be utilized, and treatment should be symptomatic.</paragraph>
                  <paragraph>Elimination of memantine can be enhanced by acidification of urine.</paragraph>
               </text>
               <effectiveTime value="20250410"/>
            </section>
         </component>
         <component>
            <section>
               <id root="32c90e66-1659-7c04-e063-6394a90ac247"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11 </content>
                  <content styleCode="bold">DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>Memantine hydrochlorideis an orally active NMDA receptor antagonist. The chemical name for memantine hydrochloride is 1-amino-3,5-dimethyladamantane hydrochloride with the following structural formula:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L39c202e4-c931-45e0-bdf6-668b0166486e"/>
                  </paragraph>
                  <paragraph>The molecular formula is C
 
  <sub>12</sub>H
 
  <sub>21</sub>NHCl and the molecular weight is 215.76. Memantine hydrochloride, USP occurs as a fine white to off-white powder and is soluble in water.

 </paragraph>
                  <paragraph>Memantine Hydrochloride Extended-Release Capsulesare supplied for oral administration as 7 mg, 14 mg, 21 mg, and 28mg capsules.Each capsule contains extended release beads with the labeled amount of memantine hydrochloride and the following inactive ingredients: ammonium hydroxide, ethylcellulose, hydroxyethyl cellulose, hypromellose, medium chain triglycerides, oleic acid, polyethylene glycol, sugar spheres and talc.</paragraph>
                  <paragraph>The capsule shell contains FD&amp;C blue 1 (14 mg, 21 mg, 28 mg), FD&amp;C yellow 6 (14 mg, 21 mg, 28 mg), gelatin, titanium dioxide and yellow iron oxide (7 mg, 14 mg).</paragraph>
                  <paragraph>The imprinting ink contains black iron oxide (7 mg, 14 mg, 21 mg), potassium hydroxide (7 mg, 14 mg, 21 mg), shellac and titanium dioxide (28 mg).</paragraph>
               </text>
               <effectiveTime value="20250410"/>
               <component>
                  <observationMedia ID="L39c202e4-c931-45e0-bdf6-668b0166486e">
                     <text>chemical structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="chemical-structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="32c90e66-165a-7c04-e063-6394a90ac247"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12 </content>
                  <content styleCode="bold">CLINICAL</content>
                  <content styleCode="bold">PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20250415"/>
               <component>
                  <section>
                     <id root="32c90e66-165b-7c04-e063-6394a90ac247"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1 </content>
                        <content styleCode="bold">Mechanism</content>
                        <content styleCode="bold">of Action</content>
                     </title>
                     <text>
                        <paragraph>Persistent activation of central nervous system N-methyl-D-aspartate (NMDA) receptors by the excitatory amino acid glutamate has been hypothesized to contribute to the symptomatology of Alzheimers disease. Memantine is postulated to exert its therapeutic effect through its action as a low to moderate affinity uncompetitive (open-channel) NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. There is no evidence that memantine prevents or slows neurodegeneration in patients with Alzheimers disease.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32c90e66-165c-7c04-e063-6394a90ac247"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.2 </content>
                        <content styleCode="bold">Pharmacodynamics</content>
                     </title>
                     <text>
                        <paragraph>Memantine showed low to negligible affinity for GABA, benzodiazepine, dopamine, adrenergic, histamine and glycine receptors and for voltage-dependent Ca
 
  <sup>2+</sup>, Na
 
  <sup>+</sup>, or K
 
  <sup>+</sup>channels. Memantine also showed antagonistic effects at the 5HT
 
  <sub>3</sub>receptor with a potency similar to that for the NMDA receptor and blocked nicotinic acetylcholine receptors with one-sixth to one-tenth the potency.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content>studies have shown that memantine does not affect the reversible inhibition of acetylcholinesterase by donepezil, galantamine, or tacrine.

 </paragraph>
                     </text>
                     <effectiveTime value="20250410"/>
                  </section>
               </component>
               <component>
                  <section ID="_12_3_Pharmacokinetics">
                     <id root="32c90e66-165d-7c04-e063-6394a90ac247"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3 </content>
                        <content styleCode="bold">Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>Memantine is well absorbed after oral administration and has linear pharmacokinetics over the therapeutic dose range. It is excreted predominantly unchanged in urine and has a terminal elimination half-life of about 60 to 80 hours. In a study comparing 28mgonce dailymemantine hydrochloride extended-release capsules to 10mgtwice daily memantine hydrochloride tablets,the C
 
  <sub>max</sub>and AUC
 
  <sub>0-24</sub>values were 48% and 33% higher for theextended-release dosage regimen, respectively.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>After multiple dose administration of memantine hydrochloride extended-release capsules, memantine peak concentrations occur around 9 to 12 hours post-dose. There is no difference in the absorption ofmemantine hydrochloride extended-release capsules when the capsule is taken intact or when the contents are sprinkled on applesauce.</paragraph>
                        <paragraph>There is no difference in memantine exposure, based on C
 
  <sub>max</sub>or AUC, formemantine hydrochloride extended-release capsules whether that drug product is administered with food or on an empty stomach. However, peak plasma concentrations are achieved about 18 hours after administration with food versus approximately 25 hours after administration on an empty stomach.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>The mean volume of distribution of memantine is 9 to 11 L/kg and the plasma protein binding is low (45%).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Memantine undergoes partial hepatic metabolism. The hepatic microsomal CYP450 enzyme system does not play a significant role in the metabolism of memantine.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Memantine is excreted predominantly unchanged in the urine and has a terminal elimination half-life of about 60 to 80 hours. About 48% of administered drug is excreted unchanged in urine; the remainder is converted primarily to three polar metabolites which possess minimal NMDA receptor antagonistic activity: the N-glucuronide conjugate, 6-hydroxy-memantine, and 1-nitroso-deaminated memantine. A total of 74% of the administered dose is excreted as the sum of the parent drug and the N-glucuronide conjugate. Renal clearance involves active tubular secretion moderated by pH dependent tubular reabsorption.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific</content>
                           <content styleCode="underline">Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Elderly</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of memantine in young and elderly subjects are similar.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gender</content>
                        </paragraph>
                        <paragraph>Following multiple dose administration of memantine hydrochloride 20mg daily, females had about 45%higher exposure than males, but there was no difference in exposure when body weight was taken into account.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Impairment</content>
                        </paragraph>
                        <paragraph>Memantine pharmacokinetics were evaluated following single oral administration of 20 mg memantine hydrochloride in 8 subjects with mild renal impairment (creatinine clearance, CLcr, &gt;50 to 80 mL/min), 8 subjects with moderate renal impairment (CLcr 30 to 49 mL/min), 7 subjects with severe renal impairment (CLcr 5 to 29 mL/min) and 8 healthy subjects (CLcr &gt;80 mL/min) matched as closely as possible by age, weight and gender to the subjects with renal impairment. Mean AUC
 
  <sub>0-</sub>increased by 4%, 60%, and 115% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects. The terminal elimination half-life increased by 18%, 41%, and 95% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>Memantine pharmacokinetics were evaluated following the administration of single oral doses of 20 mg in 8 subjects with moderate hepatic impairment (Child-Pugh Class B, score 7 to 9) and 8 subjects who were age-, gender-, and weight-matched to the hepatically impaired subjects. There was no change in memantine exposure (based on C
 
  <sub>max</sub>and AUC) in subjects with moderate hepatic impairment as compared with healthy subjects. However, terminal elimination half-life increased by about 16% in subjects with moderate hepatic impairment as compared with healthy subjects.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug-Drug Interactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Use with Cholinesterase Inhibitors</content>
                        </paragraph>
                        <paragraph>Coadministration of memantine with the AChE inhibitor donepezil did not affect the pharmacokinetics of either compound. Furthermore, memantine did not affect AChE inhibition by donepezil. In a 24-week controlled clinical study in patients with moderate to severe Alzheimers disease, the adverse reaction profile observed with a combination of memantine immediate-release and donepezil was similar to that of donepezil alone.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Memantine on the Metabolism of Other Drugs</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content>studies conducted with marker substrates of CYP450 enzymes (CYP1A2, -2A6,  2C9, -2D6, -2E1, -3A4) showed minimal inhibition of these enzymes by memantine. In addition,
 
  <content styleCode="italics">in vitro</content>studies indicate that at concentrations exceeding those associated with efficacy, memantine does not induce the cytochrome P450 isozymes CYP1A2, -2C9, 2E1 and -3A4/5. No pharmacokinetic interactions with drugs metabolized by these enzymes are expected.

 </paragraph>
                        <paragraph>Pharmacokinetic studies evaluated the potential of memantine for interaction with warfarinand bupropion. Memantine did not affect the pharmacokinetics of the CYP2B6 substrate bupropion or its metabolite hydroxybupropion. Furthermore, memantine did not affect the pharmacokinetics or pharmacodynamics of warfarin as assessed by the prothrombin INR.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Other Drugs on Memantine</content>
                        </paragraph>
                        <paragraph>Memantine is predominantly renally eliminated, and drugs that are substrates and/or inhibitors of the CYP450 system are not expected to alter the metabolism of memantine.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Drugs Eliminated via Renal Mechanisms</content>
                        </paragraph>
                        <paragraph>Because memantine is eliminated in part by tubular secretion, coadministration of drugs that use the same renal cationic system, including hydrochlorothiazide (HCTZ), triamterene (TA), metformin, cimetidine, ranitidine, quinidine, and nicotine, could potentially result in altered plasma levels of both agents. However, coadministration of memantine and HCTZ/TA did not affect the bioavailability of either memantine or TA, and the bioavailability of HCTZ decreased by 20%. In addition, coadministration of memantine with the antihyperglycemic drug Glucovance
 
  <sup></sup>(glyburide and metformin hydrochloride) did not affect the pharmacokinetics of memantine, metformin and glyburide. Furthermore, memantine did not modify the serum glucose lowering effect of Glucovance
 
  <sup></sup>, indicating the absence of a pharmacodynamic interaction.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Drugs Highly Bound to Plasma Proteins</content>
                        </paragraph>
                        <paragraph>Because the plasma protein binding of memantine is low (45%), an interaction with drugs that are highly bound to plasma proteins, such as warfarin and digoxin, is unlikely.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="32c90e66-165e-7c04-e063-6394a90ac247"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13 </content>
                  <content styleCode="bold">NONCLINICAL TOXICOLOGY</content>
               </title>
               <effectiveTime value="20250415"/>
               <component>
                  <section>
                     <id root="32c90e66-165f-7c04-e063-6394a90ac247"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1 </content>
                        <content styleCode="bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>There was no evidence of carcinogenicity in a 113-week oral study in mice at doses up to 40 mg/kg/day (7 times the maximum recommended human dose [MRHD] on a mg/m
 
  <sup>2</sup>basis). There was also no evidence of carcinogenicity in rats orally dosed at up to 40 mg/kg/day for 71 weeks followed by 20 mg/kg/day (14 and 7 times the MRHD on a mg/m
 
  <sup>2</sup>basis, respectively) through 128 weeks.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Memantine produced no evidence of genotoxic potential when evaluated in the
 
  <content styleCode="italics">in vitro S. typhimurium</content>or
 
  <content styleCode="italics">E. coli</content>reverse mutation assay, an
 
  <content styleCode="italics">in vitro</content>chromosomal aberration test in human lymphocytes, an
 
  <content styleCode="italics">in vivo</content>cytogenetics assay for chromosome damage in rats, and the
 
  <content styleCode="italics">in vivo</content>mouse micronucleus assay. The results were equivocal in an
 
  <content styleCode="italics">in vitro</content>gene mutation assay using Chinese hamster V79 cells.

 </paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>No impairment of fertility or reproductive performance was seen in rats administered up to 18 mg/kg/day (6 times the MRHD on a mg/m
 
  <sup>2</sup>basis) orally from 14 days prior to mating through gestation and lactation in females, or for 60 days prior to mating in males.

 </paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="32c90e66-1660-7c04-e063-6394a90ac247"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">13.2</content>
                        <content styleCode="bold">Animal Toxicology</content>
                        <content styleCode="bold">and/or Pharmacology</content>
                     </title>
                     <text>
                        <paragraph>Memantine induced neuronal lesions (vacuolation and necrosis) in the multipolar and pyramidal cells in cortical layers III and IV of the posterior cingulate and retrosplenial neocortices in rats, similar to those which are known to occur in rodents administered other NMDA receptor antagonists. Lesions were seen after a single dose of memantine. In a study in which rats were given daily oral doses of memantine for 14 days, the no-effect dose for neuronal necrosis was 4 times the maximum recommended human dose (MRHD of 28 mg/day) on a mg/m
 
  <sup>2</sup>basis.

 </paragraph>
                        <paragraph>In acute and repeat-dose neurotoxicity studies in female rats, oral administration of memantine and donepezil in combination resulted in increased incidence, severity, and distribution of neurodegeneration compared with memantine alone. The no-effect levels of the combination were associated with clinically relevant plasma memantine and donepezil exposures.</paragraph>
                        <paragraph>The relevance of these findings to humans is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250415"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="32c90e66-1661-7c04-e063-6394a90ac247"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14 </content>
                  <content styleCode="bold">CLINICAL STUDIES</content>
               </title>
               <text>
                  <paragraph>The effectiveness ofmemantine hydrochloride extended-release capsules as a treatment for patients with moderate to severe Alzheimers disease was based on the results of a double-blind, placebo-controlled trial.</paragraph>
                  <paragraph>
                     <content styleCode="underline">24-week Study ofMemantine Hydrochloride Extended-Release Capsules</content>
                  </paragraph>
                  <paragraph>This was a randomized double-blind clinical investigation in outpatients with moderate to severe Alzheimers disease (diagnosed by DSM-IV criteria and NINCDS-ADRDA criteria for AD with a Mini Mental State Examination (MMSE) score 3 and 14 at Screening and Baseline) receiving acetylcholinesterase inhibitor (AChEI) therapy at a stable dose for 3 months prior to screening. The mean age of patients participating in this trial was 76.5 years with a range of 49 to 97 years. Approximately 72% of patients were female and 94% were Caucasian.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Study Outcome Measures</content>
                  </paragraph>
                  <paragraph>The effectiveness ofmemantine hydrochloride extended-release capsules was evaluated in this study using the co-primary efficacy parameters of Severe Impairment Battery (SIB) and the Clinicians Interview-Based Impression of Change (CIBIC-Plus).</paragraph>
                  <paragraph>The ability ofmemantine hydrochloride extended-release capsules to improve cognitive performance was assessed with the Severe Impairment Battery (SIB), a multi-item instrument that has been validated for the evaluation of cognitive function in patients with moderate to severe dementia. The SIB examines selected aspects of cognitive performance, including elements of attention, orientation, language, memory, visuospatial ability, construction, praxis, and social interaction. The SIB scoring range is from 0 to 100, with lower scores indicating greater cognitive impairment.</paragraph>
                  <paragraph>The ability ofmemantine hydrochloride extended-release capsules to produce an overall clinical effect was assessed using a Clinicians Interview Based Impression of Change that required the use of caregiver information, the CIBIC-Plus. The CIBIC-Plus is not a single instrument and is not a standardized instrument like the ADCS-ADL or SIB. Clinical trials for investigational drugs have used a variety of CIBIC formats, each different in terms of depth and structure. As such, results from a CIBIC-Plus reflect clinical experience from the trial or trials in which it was used and cannot be compared directly with the results of CIBIC-Plus evaluations from other clinical trials. The CIBIC-Plus used in this trial was a structured instrument based on a comprehensive evaluation at baseline and subsequent time-points of four domains: general (overall clinical status), functional (including activities of daily living), cognitive, and behavioral. It represents the assessment of a skilled clinician using validated scales based on his/her observation during an interview with the patient, in combination with information supplied by a caregiver familiar with the behavior of the patient over the interval rated. The CIBIC-Plus is scored as a seven point categorical rating, ranging from a score of 1, indicating marked improvement to a score of 4, indicating no change to a score of 7, indicating marked worsening. The CIBIC-Plus has not been systematically compared directly to assessments not using information from caregivers (CIBIC) or other global methods.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Study Results</content>
                  </paragraph>
                  <paragraph>In this study, 677 patients were randomized to one of the following 2 treatments:memantine hydrochloride extended-release capsules 28mg/day or placebo while still receiving an AChEI (either donepezil, galantamine, or rivastigmine).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Effects on Severe Impairment Battery (SIB)</content>
                  </paragraph>
                  <paragraph>Figure 1 shows the time course for the change from baseline in SIB score for the two treatment groups completing the 24 weeks of the study. At 24 weeks of treatment, the mean difference in the SIB change scores for thememantine hydrochloride extended-release capsules 28mg/AChEI-treated (combination therapy) patients compared to the patients on placebo/AChEI(monotherapy) was 2.6 units. Using an LOCF analysis,memantine hydrochloride extended-release capsules 28mg/AChEI treatment was statistically significantly superior to placebo/AChEI.</paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <renderMultiMedia referencedObject="Lc544111a-5216-4fde-a955-4f3ae8029307"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Figure 1</content>
                     <content styleCode="italics">: Time course of the change from baseline in</content>
                     <content styleCode="italics">SIB score for patients completing 24 weeks of treatment</content>
                  </paragraph>
                  <paragraph>Figure 2 shows the cumulative percentages of patients from each treatment group who had attained at least the measure of improvement in SIB score shown on the X axis. The curves show that both patients assigned tomemantine hydrochloride extended-release capsules 28mg/AChEI and placebo/AChEI have a wide range of responses, but that thememantine hydrochloride extended-release capsules 28mg/AChEI group is more likely to show an improvement or a smaller decline.</paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <renderMultiMedia referencedObject="Lbc8fe448-a5cf-42ff-b087-411f0470aa24"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Figure</content>
                     <content styleCode="italics">2</content>
                     <content styleCode="italics">: Cumulative percentage of patients completing 2</content>
                     <content styleCode="italics">4</content>
                     <content styleCode="italics">weeks of</content>
                     <content styleCode="italics">double-blind treatment with specified changes from baseline in SIB scores</content>
                  </paragraph>
                  <paragraph>Figure 3 shows the time course for the CIBIC-Plus score for patients in the two treatment groups completing the 24 weeks of the study. At 24 weeks of treatment, the mean difference in the CIBIC-Plus scores for thememantine hydrochloride extended-release capsules 28mg/AChEI-treated patients compared to the patients on placebo/AChEI was 0.3 units. Using an LOCF analysis,memantine hydrochloride extended-release capsules 28mg/AChEI treatment was statistically significantly superior to placebo/AChEI.</paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <renderMultiMedia referencedObject="Lbd314b0f-c93f-4fe4-907f-da9fb979444f"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Figure 3: Time course of the CIBIC-</content>
                     <content styleCode="italics">Plus</content>
                     <content styleCode="italics">score for patients completing 24 weeks of treatment</content>
                  </paragraph>
                  <paragraph>Figure 4 is a histogram of the percentage distribution of CIBIC-Plus scores attained by patients assigned to each of the treatment groups who completed 24 weeks of treatment.</paragraph>
                  <paragraph>
                     <content styleCode="italics">
                        <renderMultiMedia referencedObject="Lf8337344-c521-4655-969a-aa35d428f6f7"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Figure 4: Distribution of CIBIC-Plus ratings at week 24</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250415"/>
               <component>
                  <observationMedia ID="Lc544111a-5216-4fde-a955-4f3ae8029307">
                     <text>figure 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lbc8fe448-a5cf-42ff-b087-411f0470aa24">
                     <text>figure 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lbd314b0f-c93f-4fe4-907f-da9fb979444f">
                     <text>figure 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="Lf8337344-c521-4655-969a-aa35d428f6f7">
                     <text>figure 4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="32c90e66-1662-7c04-e063-6394a90ac247"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16 </content>
                  <content styleCode="bold">HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>Memantine Hydrochloride Extended-Release Capsules contain 7 mg, 14 mg, 21 mg or 28 mg of memantine hydrochloride, USP.</paragraph>
                  <paragraph>
                     <content styleCode="underline">7 mg Capsule</content>
                     <br/>  Opaque buff capsule, with YH black imprint on the cap and 123 black imprint on the body. 
  <br/>  Bottle of 30 capsules with a child-resistant closure: NDC 70436-054-04

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">14 mg Capsule</content>
                     <br/>  Opaque buff cap and opaque dark green body capsule, with YH black imprint on the cap and 124 black imprint on the body. 
  <br/>  Bottle of 30 capsules with a child-resistant closure: NDC 70436-055-04 
  <br/>  Bottle of 90 capsules with a child-resistant closure: NDC 70436-055-06

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">21 mg Capsule</content>
                     <br/>  Opaque white cap and opaque dark green body capsule, with YH black imprint on the cap and 125 black imprint on the body. 
  <br/>  Bottle of 30 capsules with a child-resistant closure: NDC 70436-056-04

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">28 mg Capsule</content>
                     <br/>  Dark green opaque capsule, with YH white imprint on the cap and 126 white imprint on the body. 
  <br/>  Bottle of 30 capsules with a child-resistant closure: NDC 70436-057-04 
  <br/>  Bottle of 90 capsules with a child-resistant closure: NDC 70436-057-06

 </paragraph>
                  <paragraph>Store at 20 to 25C (68 to 77F); excursions permitted to 15 to 30C (59 to 86F) [see USP Controlled Room Temperature].Dispense in a tightly closed container as defined in the USP with a child-resistant closure.</paragraph>
                  <paragraph>Keep Memantine Hydrochloride Extended-Release Capsules and all medicines out of the reach of children.</paragraph>
               </text>
               <effectiveTime value="20250415"/>
            </section>
         </component>
         <component>
            <section>
               <id root="32c90e66-1663-7c04-e063-6394a90ac247"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17 </content>
                  <content styleCode="bold">PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (
 
  <linkHtml href="#PatientInformation">Patient Information</linkHtml>).

 </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>To assure safe and effective use of memantine hydrochloride extended-release capsules, the information and instructions provided in the patient information section should be discussed with patients and caregivers.</item>
                     <item>Instruct patients and caregivers to takememantine hydrochloride extended-release capsules only once per day, as prescribed.</item>
                     <item>Instruct patients and caregivers thatmemantine hydrochloride extended-release capsules be swallowed whole. Alternatively,memantine hydrochloride extended-release capsules may be opened and sprinkled on applesauce and the entire contents should be consumed. The capsules should not be divided, chewed or crushed.</item>
                     <item>Warn patients not to use any capsules ofmemantine hydrochloride extended-release capsules that are damaged or show signs of tampering.</item>
                     <item>If a patient misses a single dose of memantine hydrochloride extended-release capsules, that patient should not double up on the next dose. The next dose should be taken as scheduled. If a patient fails to takememantine hydrochloride extended-release capsules for several days, dosing should not be resumed without consulting that patients healthcare professional.</item>
                     <item>Advise patients and caregivers thatmemantine hydrochloride extended-release capsules may cause headache, diarrhea, and dizziness.</item>
                  </list>
                  <paragraph>Manufactured by: 
  <br/>  Yichang Humanwell Oral Solid Dosage Plant 
  <br/>  Yichang, Hubei, China 443001
 </paragraph>
                  <paragraph>Distributed by: 
  <br/>  Slate Run Pharmaceuticals, LLC 
  <br/>  Columbus, Ohio 43215
 </paragraph>
                  <paragraph>Revised: 03/2024</paragraph>
               </text>
               <effectiveTime value="20250410"/>
            </section>
         </component>
         <component>
            <section ID="PatientInformation">
               <id root="32c90e66-1664-7c04-e063-6394a90ac247"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Patient Information</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Memantine Hydrochloride (me-MAN-teen HYE-droe-KLOR-ide)</content>
                     <br/>
                     <content styleCode="bold">Extended-Release Capsules</content>
                  </paragraph>
                  <paragraph>Read this Patient Information that comes with memantine hydrochloride extended-release capsulesbefore you start taking it and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are memantine hydrochloride extended-release capsules?</content>
                  </paragraph>
                  <paragraph>Memantine hydrochloride extended-release capsules area prescription medicine used for the treatment of moderate to severe dementia in people with Alzheimers disease.Memantine hydrochloride extended-release capsules belong to a class of medicines called N-methyl-D-aspartate (NMDA) inhibitors.</paragraph>
                  <paragraph>It is not known ifmemantine hydrochloride extended-release capsules aresafe and effective in children.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Who should not take memantine hydrochloride extended-release capsules?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Do not takememantine hydrochloride extended-release capsules i</content>
                     <content styleCode="bold">f you</content>are allergic to memantine or any of the other ingredients in memantine hydrochloride extended-release capsules. See the end of this leaflet for a complete list of ingredients in memantine hydrochloride extended-release capsules.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">What should I tell my doctor before taking memantine hydrochloride extended-release capsules?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Before you take memantine hydrochloride extended-release capsules, tell your doctor if you:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>have or have had seizures</item>
                     <item>have or have had problems passing urine</item>
                     <item>have or have had bladder or kidney problems</item>
                     <item>have liver problems</item>
                     <item>have any other medical conditions</item>
                     <item>are pregnant or plan to become pregnant. It is not known ifmemantine hydrochloride extended-release capsules will harm your unborn baby.</item>
                     <item>are breastfeeding or plan to breastfeed. It is not known if memantine passes into your breast milk. Talk to your doctor about the best way to feed your baby if you take memantine hydrochloride extended-release capsules.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Tell your doctor</content>
                     <content styleCode="bold">about all the</content>
                     <content styleCode="bold">medicines you</content>
                     <content styleCode="bold">take</content>, including prescription and non-prescription medicines, vitamins, and herbal supplements.

 </paragraph>
                  <paragraph>Takingmemantine hydrochloride extended-release capsules with certain other medicines may affect each other. Takingmemantine hydrochloride extended-release capsules with other medicines can cause serious side effects.</paragraph>
                  <paragraph>Especially tell your doctor if you take:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>other NMDA antagonists such as amantadine, ketamine, and dextromethorphan</item>
                     <item>medicines that make your urine alkaline such as carbonic anhydrase inhibitors and sodium bicarbonate</item>
                  </list>
                  <paragraph>Ask your doctor or pharmacist for a list of these medicines, if you are not sure.</paragraph>
                  <paragraph>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I take memantine hydrochloride extended-release capsules?</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Your doctor will tell you how muchmemantine hydrochloride extended-release capsules to take and when to take it.</item>
                     <item>Your doctor may change your dose if needed.</item>
                     <item>Memantine hydrochloride extended-release capsulesmay be taken with food or without food.</item>
                     <item>Memantine hydrochloride extended-release capsulesmay be opened and sprinkled on applesauce before swallowing, but the contents of the entire capsule should be taken and the dose should not be divided. Except when opened and sprinkled on applesauce,memantine hydrochloride extended-release capsules must be swallowed whole and never crushed, divided or chewed.</item>
                     <item>Do not use any capsules ofmemantine hydrochloride extended-release capsules that are damaged or show signs of tampering.</item>
                     <item>If you are currently taking another formulation of memantine, talk to your healthcare professional about how to switch to memantine hydrochloride extended-release capsules.</item>
                     <item>If you forget to take one dose of memantine hydrochloride extended-release capsules, do not double up on the next dose. You should take only the next dose as scheduled.</item>
                     <item>If you have forgotten to takememantine hydrochloride extended-release capsules for several days, you should not take the next dose until you talk to your doctor.</item>
                     <item>If you take too much memantine hydrochloride extended-release capsules, call your doctor or poison control center at 1-800-222-1222, or go to the nearest hospital emergency room right away.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">What are the possible side effects of memantine hydrochloride extended-release capsules?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Memantine hydrochloride extended-release capsules may cause side effects, including:</content>
                  </paragraph>
                  <paragraph>The most common side effects ofmemantine hydrochloride extended-release capsules include:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>headache</item>
                     <item>diarrhea</item>
                     <item>dizziness</item>
                  </list>
                  <paragraph>These are not all the possible side effects of memantine hydrochloride extended-release capsules. For more information, ask your doctor or pharmacist.</paragraph>
                  <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
                  <paragraph>
                     <content styleCode="bold">How should I store memantine hydrochloride extended-release capsules?</content>
                  </paragraph>
                  <paragraph>Store at 20 to 25C (68 to 77F); excursions permitted to 15 to 30C (59 to 86F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Keep memantine hydrochloride extended-release capsules and all medicines out of the reach of children.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in memantine hydrochloride extended-release capsules?</content>
                  </paragraph>
                  <paragraph>Active ingredient: memantine hydrochloride</paragraph>
                  <paragraph>Inactive ingredients:ammonium hydroxide, ethylcellulose, hydroxyethyl cellulose, hypromellose, medium chain triglycerides, oleic acid, polyethylene glycol, sugar spheres and talc.</paragraph>
                  <paragraph>The capsule shell contains FD&amp;C blue 1 (14 mg, 21 mg, 28 mg), FD&amp;C yellow 6 (14 mg, 21 mg, 28 mg), gelatin, titanium dioxide and yellow iron oxide (7 mg, 14 mg).</paragraph>
                  <paragraph>The imprinting ink contains black iron oxide (7 mg, 14 mg, 21 mg), potassium hydroxide (7 mg, 14 mg, 21 mg), shellac and titanium dioxide (28 mg).</paragraph>
                  <paragraph>
                     <content styleCode="bold">General information about the safe and effective use of memantine hydrochloride extended-release capsules</content>
                     <content styleCode="bold">:</content>
                  </paragraph>
                  <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not takememantine hydrochloride extended-release capsules for a condition for which it was not prescribed. Do not givememantine hydrochloride extended-release capsules to other people, even if they have the same condition. It may harm them.</paragraph>
                  <paragraph>This Patient Information leaflet summarizes the most important information about memantine hydrochloride extended-release capsules. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information aboutmemantine hydrochloride extended-release capsules that was written for healthcare professionals.</paragraph>
                  <paragraph>For more information aboutmemantine hydrochloride extended-release capsules, please call Slate Run Pharmaceuticals, LLC at 1-888-341-9214.</paragraph>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>For additional copies of the Medication Guide, please visit
 
  <content styleCode="italics">www.slaterunpharma.com/products/</content>.

 </paragraph>
                  <paragraph>Manufactured by: 
  <br/>  Yichang Humanwell Oral Solid Dosage Plant 
  <br/>  Yichang, Hubei, China 443001
 </paragraph>
                  <paragraph>Distributed by: 
  <br/>  Slate Run Pharmaceuticals, LLC 
  <br/>  Columbus, Ohio 43215
 </paragraph>
                  <paragraph>Revised: 03/2024</paragraph>
               </text>
               <effectiveTime value="20250410"/>
            </section>
         </component>
         <component>
            <section ID="Lf387d76c-a56c-4baa-8333-f33c15783bd4">
               <id root="32c90e66-1665-7c04-e063-6394a90ac247"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 7 mg</content>
               </title>
               <text>
                  <paragraph>NDC 70436-054-04</paragraph>
                  <paragraph>
                     <content styleCode="bold">30 capsules</content>
                     <br/>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Once-Daily 
  <br/>
                     <content styleCode="bold">Memantine Hydrochloride Extended-Release Capsules, 7 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Ld3725a86-ec88-4f35-b5e7-17434185d8ce"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240517"/>
               <component>
                  <observationMedia ID="Ld3725a86-ec88-4f35-b5e7-17434185d8ce">
                     <text>7mg-30ct-slaterun</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="7mg-30ct-slaterun.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L8d78656c-64f7-4f43-be43-23c6149119e1">
               <id root="32c90e66-1666-7c04-e063-6394a90ac247"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 14 mg</content>
               </title>
               <text>
                  <paragraph>NDC 70436-055-04</paragraph>
                  <paragraph>
                     <content styleCode="bold">30 capsules</content>
                     <br/>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Once-Daily 
  <br/>
                     <content styleCode="bold">Memantine Hydrochloride Extended-Release Capsules, 14 mg</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="Ldf7cf15d-4b18-4edb-a238-636567928699"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>NDC 70436-055-06</paragraph>
                  <paragraph>
                     <content styleCode="bold">90 capsules</content>
                     <br/>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Once-Daily 
  <br/>
                     <content styleCode="bold">Memantine Hydrochloride Extended-Release Capsules, 14 mg</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L4d74f4bb-965a-41c7-bf4f-5960dd118958"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240517"/>
               <component>
                  <observationMedia ID="Ldf7cf15d-4b18-4edb-a238-636567928699">
                     <text>14mg-30ct-slaterun</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="14mg-30ct-slaterun.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L4d74f4bb-965a-41c7-bf4f-5960dd118958">
                     <text>14mg-90ct-slaterun</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="14mg-90ct-slaterun.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Lcffbaf10-fa27-42e0-ab44-6f1c3320f284">
               <id root="32c90e66-1667-7c04-e063-6394a90ac247"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 21 mg</content>
               </title>
               <text>
                  <paragraph>NDC 70436-056-04</paragraph>
                  <paragraph>
                     <content styleCode="bold">30 capsules</content>
                     <br/>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Once-Daily 
  <br/>
                     <content styleCode="bold">Memantine Hydrochloride Extended-Release Capsules, 21 mg</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="Ladf670fb-32fa-4e25-8167-395c112eee7b"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240517"/>
               <component>
                  <observationMedia ID="Ladf670fb-32fa-4e25-8167-395c112eee7b">
                     <text>21mg-30ct-slaterun</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="21mg-30ct-slaterun.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="L9e37a511-fb18-4529-a6a2-72ff758662f2">
               <id root="32c90e66-1668-7c04-e063-6394a90ac247"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>
                  <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 28 mg</content>
               </title>
               <text>
                  <paragraph>NDC 70436-057-04</paragraph>
                  <paragraph>
                     <content styleCode="bold">30 capsules</content>
                     <br/>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Once-Daily 
  <br/>
                     <content styleCode="bold">Memantine Hydrochloride Extended-Release Capsules, 28 mg</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L28afe1c3-d8ff-4d13-9952-b07c0f56a150"/>
                  </paragraph>
                  <paragraph/>
                  <paragraph>NDC 70436-057-06</paragraph>
                  <paragraph>
                     <content styleCode="bold">90 capsules</content>
                     <br/>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>Once-Daily 
  <br/>
                     <content styleCode="bold">Memantine Hydrochloride Extended-Release Capsules, 28 mg</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="L19a007e1-462c-4cd1-8987-47523fe7bfb0"/>
                  </paragraph>
               </text>
               <effectiveTime value="20240517"/>
               <component>
                  <observationMedia ID="L28afe1c3-d8ff-4d13-9952-b07c0f56a150">
                     <text>28mg-30ct-slaterun</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="28mg-30ct-slaterun.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="L19a007e1-462c-4cd1-8987-47523fe7bfb0">
                     <text>28mg-90ct-slaterun</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="28mg-90ct-slaterun.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>